The two faces of protein misfolding: gain‐ and loss‐of‐function in neurodegenerative diseases

The etiologies of neurodegenerative diseases may be diverse; however, a common pathological denominator is the formation of aberrant protein conformers and the occurrence of pathognomonic proteinaceous deposits. Different approaches coming from neuropathology, genetics, animal modeling and biophysics have established a crucial role of protein misfolding in the pathogenic process. However, there is an ongoing debate about the nature of the harmful proteinaceous species and how toxic conformers selectively damage neuronal populations. Increasing evidence indicates that soluble oligomers are associated with early pathological alterations, and strikingly, oligomeric assemblies of different disease‐associated proteins may share common structural features. A major step towards the understanding of mechanisms implicated in neuronal degeneration is the identification of genes, which are responsible for familial variants of neurodegenerative diseases. Studies based on these disease‐associated genes illuminated the two faces of protein misfolding in neurodegeneration: a gain of toxic function and a loss of physiological function, which can even occur in combination. Here, we summarize how these two faces of protein misfolding contribute to the pathomechanisms of Alzheimer's disease, frontotemporal lobar degeneration, Parkinson's disease and prion diseases.

[1]  D. Neary,et al.  Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43 , 2007, Acta Neuropathologica.

[2]  R. Nussbaum,et al.  Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.

[3]  C. H. Ong,et al.  Progranulin is a mediator of the wound response , 2003, Nature Medicine.

[4]  E. Buratti,et al.  An Intronic Polypyrimidine-rich Element Downstream of the Donor Site Modulates Cystic Fibrosis Transmembrane Conductance Regulator Exon 9 Alternative Splicing* , 2004, Journal of Biological Chemistry.

[5]  L. Arterburn,et al.  The Interaction between Cytoplasmic Prion Protein and the Hydrophobic Lipid Core of Membrane Correlates with Neurotoxicity* , 2006, Journal of Biological Chemistry.

[6]  A. Reichert,et al.  Loss-of-Function of Human PINK1 Results in Mitochondrial Pathology and Can Be Rescued by Parkin , 2007, The Journal of Neuroscience.

[7]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[8]  S. Prusiner Novel proteinaceous infectious particles cause scrapie. , 1982, Science.

[9]  B. Strooper Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease. , 2007 .

[10]  J. Trojanowski,et al.  Reversible Inhibition of α-Synuclein Fibrillization by Dopaminochrome-mediated Conformational Alterations* , 2005, Journal of Biological Chemistry.

[11]  C. Culmsee,et al.  Parkin Mediates Neuroprotection through Activation of IκB Kinase/Nuclear Factor-κB Signaling , 2007, The Journal of Neuroscience.

[12]  R. Krüger,et al.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.

[13]  G. Perry,et al.  Emerging evidence for the neuroprotective role of α-synuclein , 2006, Experimental Neurology.

[14]  G. Scott,et al.  Inhibition of proteasomal activity causes inclusion formation in neuronal and non-neuronal cells overexpressing Parkin. , 2003, Molecular biology of the cell.

[15]  I. Mackenzie,et al.  The molecular genetics and neuropathology of frontotemporal lobar degeneration: recent developments , 2007, Neurogenetics.

[16]  M. Cookson,et al.  Cell systems and the toxic mechanism(s) of α-synuclein , 2008, Experimental Neurology.

[17]  Xin Zhao,et al.  Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Christian von Mering,et al.  Expression of Amino-Terminally Truncated PrP in the Mouse Leading to Ataxia and Specific Cerebellar Lesions , 1998, Cell.

[19]  Patrizia Rizzu,et al.  Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism , 2002, Science.

[20]  K. Beyer Mechanistic aspects of Parkinson's disease: alpha-synuclein and the biomembrane. , 2007, Cell biochemistry and biophysics.

[21]  C. Duijn,et al.  Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21 , 2006, Nature.

[22]  B. Ghetti,et al.  Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Aβ42 production , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Jie Li,et al.  Dopamine and L‐dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  R. Nitsch,et al.  Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils , 2001, Science.

[25]  D. Harris,et al.  The cellular prion protein (PrP(C)): its physiological function and role in disease. , 2007, Biochimica et biophysica acta.

[26]  A. Brice,et al.  A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K–Akt signalling , 2006, Nature Cell Biology.

[27]  M. LaVoie,et al.  The effects of oxidative stress on parkin and other E3 ligases , 2007, Journal of neurochemistry.

[28]  Claudio L. Bassetti,et al.  Aggravation of ischemic brain injury by prion protein deficiency: Role of ERK-1/-2 and STAT-1 , 2005, Neurobiology of Disease.

[29]  M. Beal,et al.  Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Latterich,et al.  p97: The cell's molecular purgatory? , 2006, Molecular cell.

[31]  G. Drewes,et al.  Alzheimer-like paired helical filaments and antiparallel dimers formed from microtubule-associated protein tau in vitro , 1992, The Journal of cell biology.

[32]  C. Haass Take five—BACE and the γ‐secretase quartet conduct Alzheimer's amyloid β‐peptide generation , 2004 .

[33]  C. Haass,et al.  Differential Effects of Parkinson's Disease-associated Mutations on Stability and Folding of DJ-1* , 2004, Journal of Biological Chemistry.

[34]  P. Lansbury,et al.  A century-old debate on protein aggregation and neurodegeneration enters the clinic , 2006, Nature.

[35]  E. Mandelkow,et al.  Structural Principles of Tau and the Paired Helical Filaments of Alzheimer’s Disease , 2007, Brain pathology.

[36]  D. Dickson,et al.  TDP-43 in differential diagnosis of motor neuron disorders , 2007, Acta Neuropathologica.

[37]  M. Beal,et al.  Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[38]  C. Ross,et al.  Parkin Mediates Nonclassical, Proteasomal-Independent Ubiquitination of Synphilin-1: Implications for Lewy Body Formation , 2005, The Journal of Neuroscience.

[39]  S. Melquist,et al.  Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17 , 2006, Nature.

[40]  Leonidas Stefanis,et al.  Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. , 2004, Science.

[41]  T. Südhof,et al.  Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. , 2005, Cell.

[42]  O. Amaral,et al.  Increased Sensitivity to Seizures in Mice Lacking Cellular Prion Protein , 1999, Epilepsia.

[43]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[44]  J. Troncoso,et al.  S-Nitrosylation of Parkin Regulates Ubiquitination and Compromises Parkin's Protective Function , 2004, Science.

[45]  F. Cohen,et al.  Strain-specified characteristics of mouse synthetic prions. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Thomas C. Südhof,et al.  α-Synuclein Cooperates with CSPα in Preventing Neurodegeneration , 2005, Cell.

[47]  J. Collinge,et al.  Disease-associated prion protein oligomers inhibit the 26S proteasome. , 2007, Molecular cell.

[48]  Ronald C. Petersen,et al.  Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 , 1998, Nature.

[49]  C. van Broeckhoven,et al.  Frontotemporal Lobar Degeneration: Current Concepts in the Light of Recent Advances , 2007 .

[50]  E. Mandelkow,et al.  Tau in Alzheimer's disease. , 1998, Trends in cell biology.

[51]  Changcheng Song,et al.  Molecular perspectives on p97-VCP: progress in understanding its structure and diverse biological functions. , 2004, Journal of structural biology.

[52]  J. Hoenicka,et al.  The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.

[53]  A. Aguzzi,et al.  Normal host prion protein necessary for scrapie-induced neurotoxicity , 1996, Nature.

[54]  S. Pickering-Brown Progranulin and frontotemporal lobar degeneration , 2007, Acta Neuropathologica.

[55]  K. Lim,et al.  Alterations in the solubility and intracellular localization of parkin by several familial Parkinson's disease‐linked point mutations , 2005, Journal of neurochemistry.

[56]  W. Kamphorst,et al.  TDP-43 pathology in familial frontotemporal dementia and motor neuron disease without Progranulin mutations. , 2007, Brain : a journal of neurology.

[57]  C. Duijn,et al.  Tau negative frontal lobe dementia at 17q21: significant finemapping of the candidate region to a 4.8 cM interval , 2002, Molecular Psychiatry.

[58]  Andrew Lees,et al.  Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.

[59]  T. Dörk,et al.  Nuclear factor TDP‐43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping , 2001, The EMBO journal.

[60]  P. Lansbury,et al.  Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. , 2003, Biochemistry.

[61]  Miles W. Miller,et al.  Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice , 1999, Nature Medicine.

[62]  L. Petrucelli,et al.  Progranulin Mediates Caspase-Dependent Cleavage of TAR DNA Binding Protein-43 , 2007, The Journal of Neuroscience.

[63]  Rong Wang,et al.  A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity , 2001, Nature.

[64]  P. Højrup,et al.  Proteasomal inhibition by alpha-synuclein filaments and oligomers. , 2004, The Journal of biological chemistry.

[65]  D Harrich,et al.  Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs , 1995, Journal of virology.

[66]  T. Meitinger,et al.  The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. , 2006, Human molecular genetics.

[67]  Olga Pletnikova,et al.  Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function. , 2005, Human molecular genetics.

[68]  N. Hattori,et al.  Sept4, a Component of Presynaptic Scaffold and Lewy Bodies, Is Required for the Suppression of α-Synuclein Neurotoxicity , 2007, Neuron.

[69]  Li Zhang,et al.  A missense mutation (L166P) in DJ‐1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homo‐oligomerization , 2003, Journal of neurochemistry.

[70]  A. Aguzzi,et al.  Expression of truncated PrP targeted to Purkinje cells of PrP knockout mice causes Purkinje cell death and ataxia , 2003, The EMBO journal.

[71]  Smita Patel,et al.  Golgi Fragmentation Occurs in the Cells with Prefibrillar α-Synuclein Aggregates and Precedes the Formation of Fibrillar Inclusion* , 2002, The Journal of Biological Chemistry.

[72]  P. Højrup,et al.  Proteasomal Inhibition by α-Synuclein Filaments and Oligomers* , 2004, Journal of Biological Chemistry.

[73]  F. Cohen,et al.  Synthetic Mammalian Prions , 2004, Science.

[74]  D. Fushman,et al.  Polyubiquitin chains: polymeric protein signals. , 2004, Current opinion in chemical biology.

[75]  Ivan Dikic,et al.  Ubiquitylation and cell signaling , 2005, The EMBO journal.

[76]  K. Sleegers,et al.  Mutations other than null mutations producing a pathogenic loss of progranulin in frontotemporal dementia , 2007, Human mutation.

[77]  M. Ruberg,et al.  The C289G and C418R missense mutations cause rapid sequestration of human Parkin into insoluble aggregates , 2003, Neurobiology of Disease.

[78]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[79]  S. Lindquist,et al.  α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's Models , 2006, Science.

[80]  K. Lim,et al.  Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. , 2005, Human molecular genetics.

[81]  H. Kretzschmar,et al.  The Role of the Octarepeat Region in Neuroprotective Function of the Cellular Prion Protein , 2007, Brain pathology.

[82]  M. Wolfe When loss is gain: reduced presenilin proteolytic function leads to increased Abeta42/Abeta40. Talking Point on the role of presenilin mutations in Alzheimer disease. , 2007, EMBO reports.

[83]  D. Cheresh URE 3 ] as an Altered URE 2 Protein : Evidence for a Prion Analog in Saccharomyces cerevisiae , 2022 .

[84]  D. Selkoe,et al.  Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.

[85]  F. Cohen,et al.  Heritable disorder resembling neuronal storage disease in mice expressing prion protein with deletion of an α-helix , 1997, Nature Medicine.

[86]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[87]  Akira Nakashima,et al.  PHARMACOLOGY AND , 2006 .

[88]  A. Matouschek,et al.  Aggregated and Monomeric α-Synuclein Bind to the S6′ Proteasomal Protein and Inhibit Proteasomal Function* , 2003, The Journal of Biological Chemistry.

[89]  A. Pestronk,et al.  Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein , 2004, Nature Genetics.

[90]  B. Hyman,et al.  Familial Alzheimer's Disease Presenilin 1 Mutations Cause Alterations in the Conformation of Presenilin and Interactions with Amyloid Precursor Protein , 2005, The Journal of Neuroscience.

[91]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[92]  P. Lockhart,et al.  Parkin genetics: one model for Parkinson's disease. , 2004, Human molecular genetics.

[93]  J. Bell,et al.  Prion protein accumulation and neuroprotection in hypoxic brain damage. , 2004, The American journal of pathology.

[94]  Andrew B West,et al.  Molecular pathophysiology of Parkinson's disease. , 2005, Annual review of neuroscience.

[95]  Hongjun Song,et al.  Accumulation of the Authentic Parkin Substrate Aminoacyl-tRNA Synthetase Cofactor, p38/JTV-1, Leads to Catecholaminergic Cell Death , 2005, The Journal of Neuroscience.

[96]  N. Cairns,et al.  TDP‐43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations , 2007, Journal of neuropathology and experimental neurology.

[97]  S E Ide,et al.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.

[98]  Sunhong Kim,et al.  Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin , 2006, Nature.

[99]  S. Prusiner,et al.  A transmembrane form of the prion protein in neurodegenerative disease. , 1998, Science.

[100]  X. Roucou,et al.  Cellular prion protein neuroprotective function: implications in prion diseases , 2004, Journal of Molecular Medicine.

[101]  K. Lim,et al.  Relative Sensitivity of Parkin and Other Cysteine-containing Enzymes to Stress-induced Solubility Alterations* , 2007, Journal of Biological Chemistry.

[102]  David W. Miller,et al.  L166P Mutant DJ-1, Causative for Recessive Parkinson's Disease, Is Degraded through the Ubiquitin-Proteasome System* , 2003, Journal of Biological Chemistry.

[103]  J. Miyazaki,et al.  Accumulation of murine amyloidβ42 in a gene‐dosage‐dependent manner in PS1 ‘knock‐in’ mice , 1999, The European journal of neuroscience.

[104]  M. Farrer,et al.  Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. , 2004, Annals of neurology.

[105]  James E. Cleaver,et al.  Search for a Prion-Specific Nucleic Acid , 2005, Journal of Virology.

[106]  J. Hardy,et al.  Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.

[107]  D. Riesner,et al.  The polysaccharide scaffold of PrP 27-30 is a common compound of natural prions and consists of α-linked polyglucose , 2005, Biological chemistry.

[108]  E. Masliah,et al.  Anchorless Prion Protein Results in Infectious Amyloid Disease Without Clinical Scrapie , 2005, Science.

[109]  S. Bottomley,et al.  Dopamine promotes α‐synuclein aggregation into SDS‐resistant soluble oligomers via a distinct folding pathway , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[110]  A. Munnich,et al.  Spectrum of NPHP6/CEP290 mutations in Leber congenital amaurosis and delineation of the associated phenotype , 2007, Human mutation.

[111]  B. Volpe,et al.  Cross-Linking Cellular Prion Protein Triggers Neuronal Apoptosis in Vivo , 2004, Science.

[112]  M. Strong,et al.  TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein , 2007, Molecular and Cellular Neuroscience.

[113]  N. Hattori,et al.  Diverse Effects of Pathogenic Mutations of Parkin That Catalyze Multiple Monoubiquitylation in Vitro* , 2006, Journal of Biological Chemistry.

[114]  Bruce A. Yankner,et al.  Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease , 2002, Nature Medicine.

[115]  C. Weissmann,et al.  The role of PrP in health and disease. , 2004, Current molecular medicine.

[116]  B. Ghetti,et al.  Neurological Illness in Transgenic Mice Expressing a Prion Protein with an Insertional Mutation , 1998, Neuron.

[117]  I. Greenwald,et al.  Assessment of normal and mutant human presenilin function in Caenorhabditis elegans. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[118]  Hung Li,et al.  Overexpression of PrPC by Adenovirus-Mediated Gene Targeting Reduces Ischemic Injury in a Stroke Rat Model , 2005, The Journal of Neuroscience.

[119]  A. Singleton,et al.  alpha-Synuclein locus triplication causes Parkinson's disease. , 2003, Science.

[120]  David W. Miller,et al.  Kinase activity is required for the toxic effects of mutant LRRK2/dardarin , 2006, Neurobiology of Disease.

[121]  D. Flood,et al.  Presenilin-1 P264L Knock-In Mutation: Differential Effects on Aβ Production, Amyloid Deposition, and Neuronal Vulnerability , 2000, The Journal of Neuroscience.

[122]  Michela Gallagher,et al.  A specific amyloid-beta protein assembly in the brain impairs memory. , 2006, Nature.

[123]  W. Schulz-Schaeffer,et al.  Deletion of Cellular Prion Protein Results in Reduced Akt Activation, Enhanced Postischemic Caspase-3 Activation, and Exacerbation of Ischemic Brain Injury , 2006, Stroke.

[124]  David H. Cribbs,et al.  Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome , 2004, Neuron.

[125]  Thomas Meitinger,et al.  Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.

[126]  Takashi Uehara,et al.  Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[127]  Vladimir N Uversky,et al.  Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. , 2007, Journal of neurochemistry.

[128]  P. Lansbury,et al.  Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. , 2001, Biochemistry.

[129]  S. Dalal,et al.  Inclusion body myopathy-associated mutations in p97/VCP impair endoplasmic reticulum-associated degradation. , 2006, Human molecular genetics.

[130]  W. Wurst,et al.  Structural Determinants of the C-terminal Helix-Kink-Helix Motif Essential for Protein Stability and Survival Promoting Activity of DJ-1* , 2007, Journal of Biological Chemistry.

[131]  P. Lackner,et al.  Pathogenic mutations inactivate parkin by distinct mechanisms , 2005, Journal of neurochemistry.

[132]  K. Winklhofer,et al.  Inactivation of Parkin by Oxidative Stress and C-terminal Truncations , 2003, Journal of Biological Chemistry.

[133]  C. van Broeckhoven,et al.  Frontotemporal Lobar Degeneration with Ubiquitin-Positive Inclusions: A Molecular Genetic Update , 2007, Neurodegenerative Diseases.

[134]  Albert Taraboulos,et al.  Proteasomes and ubiquitin are involved in the turnover of the wild‐type prion protein , 2001, The EMBO journal.

[135]  N. Wood,et al.  Parkin is recruited into aggresomes in a stress-specific manner: over-expression of parkin reduces aggresome formation but can be dissociated from parkin's effect on neuronal survival. , 2003, Human molecular genetics.

[136]  Roger L. Williams,et al.  The emerging shape of the ESCRT machinery , 2007, Nature Reviews Molecular Cell Biology.

[137]  P. Lockhart,et al.  Parkin Protects against the Toxicity Associated with Mutant α-Synuclein Proteasome Dysfunction Selectively Affects Catecholaminergic Neurons , 2002, Neuron.

[138]  S. Lindquist,et al.  Wild-type PrP and a mutant associated with prion disease are subject to retrograde transport and proteasome degradation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[139]  J. Morris,et al.  TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. , 2007, The American journal of pathology.

[140]  Changan Jiang,et al.  Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin , 2006, Nature.

[141]  B. Caughey,et al.  Prions and their partners in crime , 2006, Nature.

[142]  M. Wolfe When loss is gain: reduced presenilin proteolytic function leads to increased Aβ42/Aβ40 , 2007 .

[143]  L. Mucke,et al.  100 Years and Counting: Prospects for Defeating Alzheimer's Disease , 2006, Science.

[144]  S. Young,et al.  ESCRT-III Dysfunction Causes Autophagosome Accumulation and Neurodegeneration , 2007, Current Biology.

[145]  Sebastian Brandner,et al.  Depleting Neuronal PrP in Prion Infection Prevents Disease and Reverses Spongiosis , 2003, Science.

[146]  V Sossi,et al.  PET studies of parkinsonism associated with mutation in the alpha-synuclein gene. , 1999, Neurology.

[147]  C. Ross,et al.  Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. , 2005, Human molecular genetics.

[148]  J. Trojanowski,et al.  Pathological TDP‐43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations , 2007, Annals of neurology.

[149]  K. Roth,et al.  Neonatal lethality in transgenic mice expressing prion protein with a deletion of residues 105–125 , 2007, The EMBO journal.

[150]  A Dürr,et al.  Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. , 2004, Lancet.

[151]  A. Aguzzi,et al.  Lethal recessive myelin toxicity of prion protein lacking its central domain , 2007, The EMBO journal.

[152]  S. Ferrari,et al.  Proteasomal Degradation and N-terminal Protease Resistance of the Codon 145 Mutant Prion Protein* , 1999, The Journal of Biological Chemistry.

[153]  T. Bartke,et al.  Association of Bcl-2 with misfolded prion protein is linked to the toxic potential of cytosolic PrP. , 2006, Molecular biology of the cell.

[154]  A. van Hoof,et al.  Messenger RNA regulation: to translate or to degrade , 2008, The EMBO journal.

[155]  L. Mucke,et al.  Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model , 2007, Science.

[156]  D. Selkoe,et al.  Dopamine covalently modifies and functionally inactivates parkin , 2005, Nature Medicine.

[157]  L. Greene,et al.  Expression of A53T Mutant But Not Wild-Type α-Synuclein in PC12 Cells Induces Alterations of the Ubiquitin-Dependent Degradation System, Loss of Dopamine Release, and Autophagic Cell Death , 2001, The Journal of Neuroscience.

[158]  B. Hyman,et al.  Nonsteroidal anti-inflammatory drugs lower Aβ42 and change presenilin 1 conformation , 2004, Nature Medicine.

[159]  C. Ross,et al.  Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[160]  W. Paschen,et al.  Endoplasmic Reticulum Stress , 2007, Annals of the New York Academy of Sciences.

[161]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[162]  P. Jones,et al.  Recent temperature trends in the Antarctic (Comment on paper by Doran et al.) , 2002 .

[163]  K. Beyer Mechanistic aspects of Parkinson’s disease: α-synuclein and the biomembrane , 2007, Cell Biochemistry and Biophysics.

[164]  J. Hardy,et al.  Progranulin mutations and ALS or ALS-FTD phenotypes , 2007 .

[165]  C. Ross,et al.  Kinase activity of mutant LRRK2 mediates neuronal toxicity , 2006, Nature Neuroscience.

[166]  T. Dawson,et al.  DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase , 2007, Proceedings of the National Academy of Sciences.

[167]  J. Morris,et al.  HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin‐positive, tau‐negative inclusions caused by a missense mutation in the signal peptide of progranulin , 2006, Annals of neurology.

[168]  A. Brice,et al.  Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity. , 2006, Human molecular genetics.

[169]  S. Itohara,et al.  Prions prevent neuronal cell-line death , 1999, Nature.

[170]  A Dürr,et al.  Causal relation between α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.

[171]  Vladimir N. Uversky,et al.  Neuropathology, biochemistry, and biophysics of α‐synuclein aggregation , 2007 .

[172]  Li Chen,et al.  α-Synuclein and Parkin Contribute to the Assembly of Ubiquitin Lysine 63-linked Multiubiquitin Chains* , 2005, Journal of Biological Chemistry.

[173]  B. Strooper,et al.  Presenilin clinical mutations can affect γ‐secretase activity by different mechanisms , 2006, Journal of neurochemistry.

[174]  C. Haass,et al.  Human presenilin-1, but not familial Alzheimer's disease (FAD) mutants, facilitate Caenorhabditis elegans Notch signalling independently of proteolytic processing. , 1997, Genes and function.

[175]  S. Squazzo,et al.  Aggregation of Secreted Amyloid -Protein into Sodium Dodecyl Sulfate-stable Oligomers in Cell Culture (*) , 1995, The Journal of Biological Chemistry.

[176]  Matthew J. Farrer,et al.  Comparison of kindreds with parkinsonism and α‐synuclein genomic multiplications , 2004 .

[177]  J. Schröder,et al.  Mean age of onset in familial Alzheimer's disease is determined by amyloid beta 42 , 2005, Neurobiology of Aging.

[178]  Keith D Wilkinson,et al.  Familial Parkinson's Disease-associated L166P Mutation Disrupts DJ-1 Protein Folding and Function* , 2004, Journal of Biological Chemistry.

[179]  C. Ross,et al.  Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. , 2001, Human molecular genetics.

[180]  Holger Hummerich,et al.  Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia , 2005, Nature Genetics.

[181]  P. Hunter Shedding a negative image , 2006, EMBO reports.

[182]  Peter T. Lansbury,et al.  Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy , 2004, Science.

[183]  A. Kakita,et al.  TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation , 2007, Acta Neuropathologica.

[184]  S. Lindquist,et al.  Neurotoxicity and Neurodegeneration When PrP Accumulates in the Cytosol , 2002, Science.

[185]  F. LaFerla,et al.  Pathways by which Abeta facilitates tau pathology. , 2006, Current Alzheimer research.

[186]  K. Winklhofer,et al.  The C-terminal Globular Domain of the Prion Protein Is Necessary and Sufficient for Import into the Endoplasmic Reticulum* , 2004, Journal of Biological Chemistry.

[187]  J. Trojanowski,et al.  Tau-mediated neurodegeneration in Alzheimer's disease and related disorders , 2007, Nature Reviews Neuroscience.

[188]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[189]  J. Hardy,et al.  Progranulin mutations and amyotrophic lateral sclerosis or amyotrophic lateral sclerosis–frontotemporal dementia phenotypes , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[190]  P. Heutink,et al.  The DJ-1L166P mutant protein associated with early onset Parkinson's disease is unstable and forms higher-order protein complexes. , 2003, Human molecular genetics.

[191]  M. Cookson,et al.  Cell systems and the toxic mechanism(s) of alpha-synuclein. , 2008, Experimental neurology.

[192]  Bruce L. Miller,et al.  Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis , 2006, Science.

[193]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[194]  T. Dawson,et al.  Identification of Far Upstream Element-binding Protein-1 as an Authentic Parkin Substrate* , 2006, Journal of Biological Chemistry.

[195]  Philippe Amouyel,et al.  α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.

[196]  R. Wickner,et al.  [URE3] as an altered URE2 protein: evidence for a prion analog in Saccharomyces cerevisiae. , 1994, Science.

[197]  P. Lockhart,et al.  RING finger 1 mutations in Parkin produce altered localization of the protein. , 2003, Human molecular genetics.

[198]  A. Aguzzi,et al.  Enhanced susceptibility of Prnp‐deficient mice to kainate‐induced seizures, neuronal apoptosis, and death: Role of AMPA/kainate receptors , 2007, Journal of neuroscience research.

[199]  F. Baralle,et al.  TDP43 depletion rescues aberrant CFTR exon 9 skipping , 2006, FEBS letters.

[200]  Philippe Amouyel,et al.  Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. , 2004, Lancet.

[201]  I. Moarefi,et al.  Determinants of the in Vivo Folding of the Prion Protein , 2003, The Journal of Biological Chemistry.

[202]  R. Martins,et al.  Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease , 2006, Molecular Psychiatry.

[203]  G. Romano,et al.  Biological activities and signaling pathways of the granulin/epithelin precursor. , 1999, Cancer research.

[204]  C. Culmsee,et al.  Parkin mediates neuroprotection through activation of IkappaB kinase/nuclear factor-kappaB signaling. , 2007, The Journal of neuroscience : the official journal of the Society for Neuroscience.